Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3

Journal of the American Academy of Dermatology

Volumn 42, Issue 6, 2000, Pages 1003-1007

  Platz, Elizabeth A ^a,d   Pollak, Michael N ^b   Willett, Walter C ^a,c   Giovannucci, Edward ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; GENE EXPRESSION; HAIR FOLLICLE; HAIR GROWTH; HAIR LOSS; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0034120183     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.103987     Document Type: Article

References (26)

1. Demark-Wahnefried W, Lesko SM, Conaway MR, Robertson CN, Clark RV, Logaugh B, et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 1997;18:495-500.
2. Signorello LB, Wuu J, Hsieh C-c, Tzonou A, Trichopoulos D, Mantzoros CS. Hormones and hair patterning in men: a role for insulin-like growth factor 1? J Am Acad Dermatol 1999;40:200-3.
3. Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975;68:1359-65.
4. Olsen EA, Weiner MS, Delong ER, Pinnell SR. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol 1985;13:185-92.
5. Rosner B. Fundamentals of biostatistics. Boston: Duxbury Press; 1986.
6. Willett WC. Nutritional epidemiology. New York: Oxford University Press; 1990.
7. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold; 1982.
8. Cohen P, Rosenfeld RG. The insulin-like growth factor axis. In: Shiverick KT, Rosenbloom AL, editors. Human growth hormone pharmacology: basic and clinical aspects. Boca Raton: CRC Press; 1995. p. 43-55.
9. Philpott MP, Sanders DA, Kealey T. Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-1 at physiologic concentrations is an important regulator of hair follicle growth in vitro. J Invest Dermatol 1994;102:857-61.
10. Peus D, Pittelkow MR. Growth factors in hair organ development and the hair growth cycle. Dermatol Clin 1996;4:559-72.
11. Itami S, Kurata S, Takayasu S. Androgen induction of follicular epithelial cell growth is mediated via insulin-like growth factors-1 from dermal papilla cells. Biochem Biophys Res Commun 1995;212:988.
12. Horton R, Pasupuletti V, Antonipillai I. Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endocrinol 1993;133:447-51.
13. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39:578-89.
14. Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor-I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 1998;58:215-8.
15. Leroith D, Roberts Jr CT. Growth factors and cytokines. In: Becker K, editor. Principles and practice of endocrinology and metabolism. Philadelphia: JB Lippincott; 1995. p. 1451-65.
16. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
17. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8.
18. Wolk A, Mantzoros CS, Andersson SW, Bergström R, Signorello LB, Lagiou P, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
19. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al. Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 1993;29A:492-7.
20. Bruning PF, Van Doom J, Bonfrèr JMG, Van Noord PAH, Korse CM, Linders TC, et al. Insulin-like growth-factor binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62:266-70.
21. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
22. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998;9:570-3.
23. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao YZ, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
24. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-7.
25. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women: the Rancho Bernardo Study. Am J Epidemiol 1997;145:970-6.
26. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107-10.